Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

600276

株式のランク #544
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
株価
$6.89
時価総額
$43.94B
変化(1日)
-2.91%
変化(1年)
-24.78%
国
CN
取引 Jiangsu Hengrui Medicine Co., Ltd. (600276)

カテゴリー

Healthcare
Jiangsu Hengrui Medicine Co., Ltd.(600276)の収益
Oct 2026 時点の収益 TTM: 0
Jiangsu Hengrui Medicine Co., Ltd. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Jiangsu Hengrui Medicine Co., Ltd. の収益履歴(2001 ~ 2026)
各年末の収益
年 収益 変化
2025 $4.49B 17.17%
2024 $3.83B 18.93%
2023 $3.22B 4.52%
2022 $3.08B -24.33%
2021 $4.08B -4.00%
2020 $4.25B 26.94%
2019 $3.34B 32.08%
2018 $2.53B 19.08%
2017 $2.13B 33.09%
2016 $1.60B 11.38%
2015 $1.43B 19.24%
2014 $1.20B 17.65%
2013 $1.02B 17.33%
2012 $871.59M 20.75%
2011 $721.81M 27.25%
2010 $567.25M 27.86%
2009 $443.66M 26.53%
2008 $350.63M 30.64%
2007 $268.38M 47.29%
2006 $182.22M 24.73%
2005 $146.10M 5.58%
2004 $138.38M 9.03%
2003 $126.92M 38.95%
2002 $91.34M 19.17%
2001 $76.65M 0.00%